The power of three in severe asthma

 

Asthma can be mild, moderate, or severe. A small group of people may have severe or poorly controlled asthma despite treatment because they possess an eosonophilic phenotyope in their white blood cells that contributes to inflammation in the lungs. It’s often called e-asthma.

 

Teva asked Nukleus to explore a range of ways to express the main benefits of their new therapy, CINQAIR, to professionals. As the first treatment especially for e-asthma, CINQAIR helps deliver 3 key effects–fewer attacks, better breathing and better symptom control. And Nukleus delivered with a trio of compelling creative campaigns to highlight the condition and the solution.